Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study [0.03%]
度伐利尤单抗联合化疗治疗晚期胆道癌的III期TOPAZ-1研究最新三年总生存数据更新
Do-Youn Oh,Aiwu Ruth He,Shukui Qin et al.
Do-Youn Oh et al.
Background: At the TOPAZ-1 (NCT03875235) primary analysis, durvalumab plus gemcitabine and cisplatin (GemCis) significantly improved overall survival (OS) in advanced biliary tract cancer (aBTC). We report updated explora...
Establishing five-year overall survival as a new standard for trials in advanced HCC [0.03%]
在晚期肝细胞癌试验中建立五年总生存率作为新的标准指标
Pierre Nahon
Pierre Nahon
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial [0.03%]
Elafibranor在原发性硬化性胆管炎中的安全性和有效性：ELMWOOD二期随机对照试验
Cynthia Levy,George F Abouda,Bahri M Bilir et al.
Cynthia Levy et al.
Background & aims: Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease. Elafibranor, a dual peroxisome proliferator-activated receptor-α/δ agonist, was investigated in the phase II ELMWOOD trial (NCT05...
Overcoming drug resistance by harnessing mitochondrial divisome for treating cholangiocarcinoma [0.03%]
利用线粒体分裂机器克服胆管癌药物抗性治疗
Mengwei Niu,Wen-Xing Ding
Mengwei Niu
EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma [0.03%]
欧洲肝脏研究学会(EASL)关于肝外胆管癌管理的临床实践指南
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
Recent years have witnessed significant advances in the imaging, molecular profiling, and systemic treatment of cholangiocarcinoma (CCA). Despite this progress, the early detection, precise classification, and effective management of CCA re...
Practice Guideline
Journal of hepatology. 2025 Apr 30:S0168-8278(25)00162-X. DOI:10.1016/j.jhep.2025.03.007 2025
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis [0.03%]
欧洲肝脏研究学会自身免疫性肝炎管理指南
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown aetiology which may affect any patient irrespective of age, sex, and ethnicity. At baseline, the clinical spectrum of the disease varies largely from asymptomatic cases to acu...
Practice Guideline
Journal of hepatology. 2025 May 8:S0168-8278(25)00173-4. DOI:10.1016/j.jhep.2025.03.017 2025
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection [0.03%]
欧洲肝脏研究学会乙肝病毒感染管理指南
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostic...
Practice Guideline
Journal of hepatology. 2025 May 8:S0168-8278(25)00174-6. DOI:10.1016/j.jhep.2025.03.018 2025
EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease [0.03%]
欧洲肝脏研究学会肝硬化和晚期慢性肝病患者腹部外科手术临床实践指南
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
Extrahepatic surgery in patients with cirrhosis of the liver represents a growing clinical challenge due to the increasing prevalence of chronic liver disease and improved long-term survival of these patients. The presence of cirrhosis sign...
Practice Guideline
Journal of hepatology. 2025 May 8:S0168-8278(25)00235-1. DOI:10.1016/j.jhep.2025.04.008 2025
Decoding the Resistin-CAP1 Pathway in Intermediate Monocytes Mediating Liver Allograft Rejection [0.03%]
解码中间单核细胞中介导的肝移植排斥反应中的Resistin-CAP1信号通路
Peijun Yang,Xudan Wang,Weikang Wu et al.
Peijun Yang et al.
Background & aims: Lymphocytes are widely recognized as the primary mediators of cellular rejection post-liver transplantation. However, conventional immunosuppressive regimens that target lymphocytes, such as calcineurin...